Horizon 2020 Szechenyi 2020
CLOSE Return to home page Highly Efficacious

In cancer, 20-30% of patients die due to cachexia and more than 50% of patients with cancer die with cachexia being present. An underlying chronic inflammation and the hypercatabolic and hypermetabolic state in malignant diseases lead to the development of cachexia. In addition to the altered nutritional needs of cancer patients, the tumor itself is characterized with an altered metabolism that allows mainly the use of carbohydrates as energy source for the cancer cells.

Our pipeline includes a product that is designed to address these needs.

Clinical research of the past decade has shown that specific conditions require specific medical nutrition. According to these scientific findings and based on an approach focusing on patients and conditions we are currently working to identify the specific nutritional needs of many different illnesses in order to develop products which address these needs.

To read more about our development strategy and on-going research, click here.